Cantor Fitzgerald provided analyst coverage and targets for Esperion Therapeutics.
1 report, 1 independent
Updated Jun 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald provided analyst coverage and targets for Esperion Therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
- The event reports that Brooke Rollins serves as Trump's Agriculture Secretary and notes that Lutnick previously ran Cantor Fitzgerald.
- Agilysys CEO Ramesh Srinivasan sold significant company shares, with the transaction disclosed via filings with the SEC, concurrent with a rating from Cantor Fitzgerald.
-
Esperion Therapeutics
American pharmaceutical company
Nothing else this week.
Related events
- Cantor Fitzgerald initiated stock coverage on AgomAB Therapeutics, and Director David Epstein acquired company stock.
- Cantor Fitzgerald began coverage and issued rating, and Morgan Stanley upgraded price objective and rating for Silence Therapeutics.
- Analyst provides a high price target for Viking Therapeutics stock.
- Cantor Fitzgerald restated an overweight rating and Royal Bank of Canada reduced its price objective for United Therapeutics.
- Cantor Fitzgerald restated an overweight rating for Anteris Technologies Global Corp. on October 8, 2026.